Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IMA 203

Next Previous
Drug Profile

IMA 203

Alternative Names: IMA-203; IMA-203CD8; IMA203-GEN1; IMA203-GEN2

Latest Information Update: 08 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Immatics US
  • Developer Bristol-Myers Squibb; Immatics US; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Haematological malignancies; Solid tumours

Most Recent Events

  • 21 Mar 2024 Immatics N.V. plans a registration-enabling randomised phase II/III trial in 2024 for IMA203 GEN1 in Malignant melanoma (Second-line therapy or greater) or later (2L+) cutaneous melanoma(2L+) cutaneous melanoma, potentially including also uveal melanoma patients in USA (IV, Infusion) in 2024
  • 14 Nov 2023 Updated efficacy, pharmacokinetics and safety data from a phase I trial in Solid tumours released by Immatics N.V.
  • 24 Oct 2023 IMA 203 receives Regenerative Medicine Advanced Therapy (RMAT) status for Solid tumours (Recurrent, Refractory metastatic disease) in USA
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top